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The proteasome machinery has been shown to provideMycobacterium tuberculosis (Mtb) with the ability to
protect itself from the damaging effects of reactive nitrogen intermediates. In their recent paper, Darwin and
colleagues identify the protein modifier inMtb that targets substrates for degradation in theMtb proteasome.Tuberculosis is primarily acquired through
inhalation of airborne droplets containing
Mycobacterium tuberculosis (Mtb). Sub-
sequently, the bacteria travel to distal
regions of the lung and are engulfed by
resident macrophages. Mtb engages
several different phagocytic receptors to
invade the macrophage, and once inside
it successfully evades destruction by the
innate microbicidal machinery. Seminal
studies performed nearly three decades
ago by Armstrong and D’Arcy Hart (Arm-
strong and Hart, 1975) have shaped our
understanding of how Mtb might resist
killing inside the macrophage. Their work
showed that Mtb vacuoles did not fuse
with the lysosomal compartment. Sub-
stantive work from independent investi-
gators (Russell, 2007) has expanded on
this paradigm to provide a detailed under-
standing of the molecular events that
arrest the maturation of the Mtb phago-
some and prevent its normal biogenesis
and progression to fusion with the lyso-
somal compartment. In the battle of the
host against pathogen, the first round
goes to Mtb.
As the battle progresses, the host
counteracts through the activation of
adaptive immunity. By inducing immu-
nity-related GTPase Irgm1 and activating
the autophagy pathway in infected cells,
IFN-g, a key Th1 effector molecule of the
adaptive immune compartment, is able
to revoke the restriction on Mtb phago-
some maturation and expose Mtb to the
antimicrobial contents of the lysosomal
compartment (Deretic, 2006). IFN-g, in
conjunction with TNF, upregulates NOS2
and facilitates the production of reactive
oxygen and reactive nitrogen intermedi-
ates (RNI) within the phagolysosome,resulting in Mtb killing (Nathan and Shiloh,
2000). In vivo, as the battle progresses,
an orchestrated series of Th1 dominant
adaptive immune pathways are activated
to culminate in a granuloma at the initial
foci of infection (Russell, 2007). At this
stage, the mycobacteria are contained
within the granuloma with minimal collat-
eral damage to lung tissue. The second
round goes to the host macrophage.
A few conniving bacteria, however,
escape the damaging effects of RNI and
other toxic molecules generated within
the phagosomes. These bacteria continue
to persist as nonreplicative forms with the
ability to reactivate later and continue the
cycle of human to human transmission.
The third round goes to Mtb.
Clearly, Mtb is equipped with defense
mechanisms that can counteract host-
induced oxidative and nitrosative stress
to ultimately emerge as the winner. Na-
than and colleagues identified Mtb genes
that provide defense against RNI (Darwin
et al., 2003). They screened a library of
10,000 Mtb transposon mutants for NO
sensitivity and identified mutants with in-
sertions in proteasome associated genes,
mpa and pafA, providing the first clue that
the proteasome pathway afforded Mtb
a means to protect itself from toxic RNI.
The authors also showed that the mpa
gene encoded an ATPase that shared
homology with ATPases found in the
regulatory cap of the eukaryotic 26S
proteasome and most likely functioned
in channeling proteins to the proteosome
core, while the pafA gene was shown to
encode for a proteasome accessory fac-
tor. Both mpa and pafA mutants of Mtb
were attenuated in mice, signifying the
importance of the proteasome pathwayCell Host & Microbe 4, Nto Mtb survival in vivo. Furthermore, this
study also demonstrated that specific
inhibitors of the proteasome prevented
Mtb growth and its ability to resist the
toxic effects of RNI. Subsequently, Dar-
win and colleagues (Pearce et al., 2006)
identified FabD and PanB, enzymes in-
volved in the biosynthesis of fatty acids
and polyketides, as the natural substrates
of the Mtb proteasome. Although these
studies provided direct evidence that
Mpa and PafA, together with the protea-
some protease, regulate protein degrada-
tion and disposal in Mtb, additional
substrate characterization is required to
exactly define the mechanism behind the
attenuated virulence of the mpa and
pafA mutants.
The studies so far establish that the pro-
teasome regulates Mtb growth in vivo;
however, the essentiality of the protea-
some to Mtb persistence in vivo was
validated in a report from Ehrt’s group
(Gandotra et al., 2007). The authors dem-
onstrated that conditional silencing of
prcBA, genes encoding Mtb’s gated pro-
teasome core, during chronic infection,
prevented bacterial persistence. Interest-
ingly, IFN-g/ mice infected with pro-
teasome-silenced Mtb had a moderately
better survival rate in comparison with
mice infected with Mtb containing intact
proteasome, suggesting a more multifac-
eted role for the proteasome in regulating
Mtb growth in vivo.
Together, these studies strongly sup-
port thatMtbuses its proteasomemachin-
ery to adapt to the host microenvironment
and achieve its persistent lifestyle. How-
ever, as this storyline developed, a piece
of information that was still missing was
the process that marked Mtb proteinsovember 13, 2008 ª2008 Elsevier Inc. 415
Cell Host & Microbe
Previewsand designated them for degradation in
the proteasome. In eukaryotes, proteins
selected for proteasome-mediated re-
moval are tagged with polyubiquitin
chains for recognition by the proteasome
machinery, but genes encoding this pro-
tein modifier have not been identified in
the Mtb genome. The missing piece to
the story was recently provided in elegant
studies by Darwin and colleagues (Pearce
et al., 2008), in which they identified a
prokaryotic ubiquitin-like protein, Pup, as
the Mtb equivalent of the eukaryotic pro-
teinmodifier ubiquitin. The authors coined
the term pupylation to describe the pro-
cess of conjugation of Pup to its protea-
some substrates. Using tandem affinity
chromatography to purify pupylated sub-
strates and subsequent mass spectro-
metric characterization of the interaction
between Pup and the substrate revealed
that pupylation occurred on specific lysine
residues of protein substrates prior to
degradation, similar towhat is seen during
ubiquitylation. Absence of pupylated pro-
teins with attendant accumulation of sub-
strates in PafA mutants provided direct
proof that pupylated proteins are destined
for degradation.
In eukaryotic organisms, targeted elim-
ination of proteins by the ubiquitin-protea-
some pathway is crucial to the regulation
of several cellular processes. It would
be interesting to see if in an analogous
manner the Pup-proteasome pathway
also has multifaceted functions in Mtb.
Furthermore, using rabbit and guinea pig416 Cell Host & Microbe 4, November 13, 200models, it will be important to ascertain
whether the proteasomal pathway plays
a role in Mtb’s ability to survive within
hypoxic granulomas. Can the role of the
proteasome be extended to protection
from other insults, besides nitrosative, in-
side the macrophage? It would be worth
exploring if Mtb will use a similar mecha-
nism of removal of damaged proteins via
the proteasome to resist antimicrobial
peptides such as cathelicidins that block
Mtb proliferation in human macrophages
(Liu et al., 2006).
Notwithstanding these questions, the
Mtb proteasome studies indicate that
this machinery is not only necessary for
Mtb to survive and replicate in the host,
but importantly it is also essential for its
ability to persist in the host in a nonreplica-
tive state. The identification of Pup as the
protein modifier in the Mtb proteasome
pathway (Pearce et al., 2008) provides
a great means to identify and characterize
Mtb substrates targeted for the protea-
some. Identification of such substrates
will then distinguish Mtb pathways in-
volved in its in vivo survival and form the
basis of rational drug design. Indeed, the
Mtb proteasome has already proven
useful in this regard. Recent work has
identified that a certain class of chemical
inhibitors called rhodanines can inhibit
dihydrolipoamide acyltrasferase, an en-
zyme required by Mtb to resist the action
of RNI (Bryk et al., 2008). Clearly, the Mtb
proteasome pathway is an exciting area
for discovering new classes of Mtb drug8 ª2008 Elsevier Inc.targets. The host might have lost the bat-
tle, but it might just survive to win the war!ACKNOWLEDGMENTS
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